tutorial

Upper Tract Urothelial Carcinoma Care Tech Platform Monitoring Guide 2026

"A comprehensive guide to monitoring digital health platforms supporting UTUC care, covering Lynch syndrome MSI/MMR result routing, contralateral kidney surveillance, adjuvant nivolumab scheduling, and FGFR3 molecular result workflows."

Upper Tract Urothelial Carcinoma Care Tech Platform Monitoring Guide 2026

Overview

Upper tract urothelial carcinoma (UTUC) encompasses urothelial malignancies arising in the renal pelvis and ureter, accounting for approximately 5–10% of all urothelial cancers. Though uncommon relative to bladder cancer, UTUC carries distinct clinical significance: it is strongly associated with Lynch syndrome in up to 5–15% of cases, and its anatomical location in the upper urinary tract makes organ-sparing endoscopic management feasible only in select low-grade, solitary lesions. High-grade or invasive UTUC is managed primarily with radical nephroureterectomy (RNU), with adjuvant nivolumab now representing a meaningful advance in reducing recurrence risk for pT2–pT4 or node-positive disease (based on CheckMate 274 data in the urothelial population).

The metastatic UTUC landscape mirrors that of bladder urothelial cancer, with platinum-based chemotherapy as backbone and targeted options for FGFR3-altered tumors — erdafitinib (pan-FGFR inhibitor) and enfortumab vedotin (nectin-4-directed ADC) — now part of the therapeutic armamentarium. FGFR3 alterations occur in a meaningful fraction of UTUC, particularly the low-grade subtype, making molecular profiling a routine part of metastatic workup.

The digital health platforms supporting UTUC care must coordinate across urology, oncology, genetic counseling, radiology, and molecular pathology. Unlike many GU malignancies, UTUC's Lynch syndrome association introduces a hereditary cancer management dimension that requires integration with genetic testing laboratories, family history systems, and germline result routing engines. This guide describes how to monitor the technology platforms enabling high-quality UTUC care.

Care Technology Landscape

Pathology and Molecular Testing Information Systems — UTUC pathology reports must capture histologic grade, T-stage, margin status, and — critically — MMR protein expression by immunohistochemistry (IHC) and/or MSI status by PCR or next-generation sequencing. Results from MMR IHC and MSI testing must route to the treating urologist and genetic counselor, trigger Lynch syndrome reflex testing workflows, and — when MSI-high or dMMR is confirmed — prompt germline testing referral.

Genetic Counseling and Germline Routing Platforms — Lynch syndrome is caused by germline pathogenic variants in MMR genes (MLH1, MSH2, MSH6, PMS2; EPCAM deletions affecting MSH2). A positive IHC/MSI screen at the tumor level must trigger a structured pathway: genetic counseling referral, germline blood-based testing, and — for confirmed Lynch syndrome — cascade testing outreach to first-degree relatives. Clinical informatics platforms managing these workflows require careful monitoring to prevent results from stalling at any handoff point.

Radiology and Surveillance Scheduling Systems — Contralateral kidney surveillance following RNU is essential, as UTUC patients face a 15–25% risk of metachronous bladder tumors and a smaller but meaningful risk of contralateral upper tract recurrence. Surveillance protocols typically include urine cytology (every 3–6 months for 5 years) and CT urogram (annually for 5 years). Scheduling platforms must track these intervals, generate outreach when studies become due, and link results to the clinical encounter.

Adjuvant Immunotherapy Scheduling Platforms — Adjuvant nivolumab following RNU requires a defined treatment schedule (240 mg every 2 weeks or 480 mg every 4 weeks for up to 1 year). Oncology information systems (OIS) must manage cycle scheduling, pre-medication verification, and toxicity surveillance integration — including irAE monitoring analogous to that used in metastatic settings.

FGFR3 Molecular Result Routing Systems — For metastatic UTUC, comprehensive genomic profiling (CGP) panels detect FGFR3 point mutations (R248C, S249C, G370C, Y373C) and fusions (FGFR3-TACC3). Results from CGP laboratories (Foundation Medicine, Tempus, Caris) must route to the treating oncologist, generate FGFR3-targeted therapy eligibility flags, and — for erdafitinib — trigger ophthalmology referral workflows (central serous retinopathy monitoring requirement).

Key Monitoring Metrics

Lynch Syndrome MSI/MMR Testing Result Routing

Test Ordering Completeness

  • UTUC resection specimens with MMR IHC or MSI testing ordered: compliance rate (target: 100% for all invasive cases per institutional protocol)
  • Reflex MMR testing ordered automatically at time of pathology sign-out: automation rate vs. manual order rate
  • Time from specimen receipt to MMR IHC result availability (target: < 5 business days)

Result Routing

  • MMR IHC or MSI results successfully routed to ordering urologist within 4 hours of sign-out: routing success rate
  • Results routed to genetic counseling service for dMMR/MSI-H cases within 1 business day: SLA compliance rate
  • Germline testing referral created within 5 business days of dMMR/MSI-H confirmation: referral generation rate

Downstream Genetic Counseling Integration

  • Genetic counseling appointments scheduled within 21 days of referral for Lynch syndrome workup: scheduling rate
  • Germline testing result availability within 28 days of blood draw: lab turnaround tracking
  • Confirmed Lynch syndrome cases with cascade testing outreach to first-degree relatives initiated: completion rate

Alert Metrics

  • dMMR/MSI-H result with no downstream genetic counseling referral created within 5 business days: flag and alert
  • Germline pathogenic MMR variant result with no cascade testing letter generated within 14 days: flag

Contralateral Kidney Surveillance

Surveillance Protocol Adherence

  • Post-RNU surveillance protocol activated at time of discharge order or first follow-up visit: generation rate (target: 100%)
  • Current guideline version applied to schedule generation: alert when outdated protocol version is active
  • Surveillance interval correctness: automated audit comparing scheduled intervals to NCCN/EAU protocol recommendations

Urine Cytology Tracking

  • Urine cytology ordered per protocol interval (every 3–6 months, year 1–5): order compliance rate
  • Cytology results routed to urologist within 24 hours of result: routing rate
  • Atypical or malignant cytology results triggering urgent cystoscopy scheduling: alert generation rate and time-to-action

CT Urogram Scheduling

  • Annual CT urogram scheduled and completed within the protocol window (± 30 days): on-time completion rate
  • Time from CT urogram order to scheduled appointment (target: < 14 business days)
  • CT urogram reports with new upper tract abnormality triggering urology urgent appointment: detection rate

Bladder Surveillance Integration

  • Cystoscopy ordered per protocol for post-RNU bladder surveillance: compliance rate
  • Bladder recurrence detected and triggering TURBT referral within 10 business days: time-to-action tracking

Adjuvant Nivolumab Scheduling

Treatment Schedule Integrity

  • Cycle 1 nivolumab administered within 90 days of RNU: on-time start rate
  • Subsequent cycles administered within protocol-specified windows (every 2 or 4 weeks ± 7 days): cycle timing compliance rate
  • Treatment cycle delays logged with reason codes: reason code capture rate

Pre-Infusion Verification

  • Pre-cycle performance status and toxicity assessment completed before each cycle: documentation rate
  • Creatinine, LFT, and thyroid function labs resulted and reviewed before each cycle: order compliance and result review rate
  • Dose modifications or holds triggered by irAE appropriately documented in OIS: compliance rate

irAE Surveillance for Adjuvant Setting

  • PRO toxicity survey completion rate during adjuvant nivolumab (target: > 80%)
  • Grade ≥ 2 irAE detected and resulting in protocol-specified management within 48 hours: response rate
  • Adjuvant treatment completion rate at 1 year: population-level tracking for quality benchmarking

FGFR3 Molecular Result Routing

CGP Test Ordering

  • Metastatic UTUC patients with CGP ordered at time of metastatic diagnosis: ordering rate (target: 100% per institutional protocol)
  • Time from tissue submission to CGP report availability (track by laboratory partner): median and 90th percentile turnaround
  • CGP report receipt confirmed in interface engine: acknowledgment rate

FGFR3 Variant Result Routing

  • FGFR3-altered results routed to treating oncologist within 4 hours of CGP report receipt: routing success rate
  • FGFR3 eligibility flag created in OIS within 24 hours of confirmed FGFR3 alteration: flag creation rate
  • Erdafitinib ophthalmology referral order generated for FGFR3-altered patients beginning erdafitinib: referral automation rate

FGFR3 Inhibitor Toxicity Monitoring

  • Baseline and cycle ophthalmology assessments scheduled per erdafitinib protocol: scheduling compliance
  • Phosphate level monitoring (hyperphosphatemia is a class effect of FGFR inhibition) ordered per cycle: lab order compliance
  • Phosphate > 7 mg/dL detection-to-alert time: target < 2 hours from result

Platform Setup

UTUC Observability Stack

Deploy monitoring across all UTUC care platform components:

# Prometheus scrape config for UTUC platforms
scrape_configs:
  - job_name: msi_mmr_routing_engine
    static_configs:
      - targets: ['msi-router.internal:9090']
    scrape_interval: 30s

  - job_name: genetic_counseling_scheduler
    static_configs:
      - targets: ['gc-scheduler.internal:9090']
    scrape_interval: 60s

  - job_name: surveillance_scheduler
    static_configs:
      - targets: ['surveillance-sched.internal:9090']
    scrape_interval: 120s

  - job_name: adjuvant_ois_nivolumab
    static_configs:
      - targets: ['ois-adjuvant.internal:9090']
    scrape_interval: 30s

  - job_name: fgfr3_molecular_router
    static_configs:
      - targets: ['cgp-router.internal:9090']
    scrape_interval: 30s

Lynch Syndrome Routing Canary

Implement a synthetic transaction that simulates the full Lynch syndrome reflex pathway:

# Pseudocode: Lynch syndrome routing canary
def run_lynch_routing_canary():
    test_specimen_id = "CANARY-UTUC-PATH-001"
    # Inject synthetic dMMR IHC result (MLH1 loss)
    inject_pathology_result(
        specimen_id=test_specimen_id,
        result_type="MMR_IHC",
        findings={"MLH1": "absent", "PMS2": "absent", "MSH2": "present", "MSH6": "present"}
    )
    start = time.now()
    # Verify genetic counseling referral created
    referral = poll_for_referral(test_specimen_id, referral_type="genetic_counseling", timeout=86400)
    latency = time.now() - start
    metrics.record("lynch_routing_canary_latency_seconds", latency)
    if referral is None:
        alert("UTUC Lynch routing canary: dMMR result did not generate GC referral within 24h SLA")

Surveillance Schedule Validator

Run a nightly batch job to validate that all post-RNU patients have active surveillance schedules with upcoming appointments within protocol windows:

# Pseudocode: surveillance schedule validator
def validate_utuc_surveillance_schedules():
    post_rnu_patients = query_ehr("SELECT patient_id FROM procedures WHERE procedure = 'RNU' AND date > now() - 5 years")
    for patient_id in post_rnu_patients:
        schedule = get_surveillance_schedule(patient_id)
        if schedule is None:
            flag_missing_schedule(patient_id)
        else:
            next_due = schedule.next_due_date()
            if next_due < today + timedelta(days=14) and not schedule.has_upcoming_appointment():
                flag_overdue_without_appointment(patient_id, next_due)

FGFR3 Alert Integration with Ophthalmology

For institutions offering erdafitinib:

  • Configure an EHR alert rule: when erdafitinib is ordered for a patient without an ophthalmology referral, surface a hard stop requiring referral order entry
  • Monitor hard-stop override rate: ophthalmologists should review 100% of cases; a high override rate indicates workflow friction
  • Track ophthalmology appointment completion rate before cycle 1 erdafitinib infusion

Alerting Strategies

Severity Tiering

P1 — Immediate Clinical Impact

  • MSI/MMR result routing engine down; pathologic dMMR results not reaching genetic counseling service
  • CGP molecular result routing engine down; FGFR3 results not reaching oncologist
  • Adjuvant nivolumab OIS scheduling system unavailable; cycle treatment cannot be authorized
  • Erdafitinib phosphate monitoring alert system down; hyperphosphatemia toxicity not being detected

P2 — Degraded Operation

  • dMMR/MSI-H result not routed to genetic counseling within 2 business days (SLA breach)
  • Post-RNU surveillance schedule missing for patient approaching first surveillance interval
  • Adjuvant nivolumab cycle adherence drop > 20% from baseline (may indicate scheduling system failure)
  • FGFR3 eligibility flag not created within 48 hours of CGP report receipt

P3 — Quality/Compliance

  • CGP ordering rate for metastatic UTUC patients < 90% over rolling 30-day period
  • Germline testing referral completion rate < 85% for dMMR cases: audit and root cause
  • Ophthalmology referral automation rate for erdafitinib starters < 95%: process review

Routing the Right Alerts to the Right Teams

Establish separate alert destinations for clinical and engineering concerns:

  • MSI/MMR routing failures → clinical informatics on-call + genetic counseling department head (during business hours)
  • CGP routing failures → oncology informatics engineer + molecular tumor board coordinator
  • Surveillance scheduling gaps → care coordination team + urology nursing staff
  • Platform-level outages → engineering on-call via PagerDuty

Avoid alert fatigue by ensuring P3 alerts route exclusively to a daily digest report rather than synchronous channels.

Conclusion

UTUC's relatively rare occurrence belies the complexity of its clinical and informatics infrastructure requirements. The Lynch syndrome association demands a vigilant result-routing system that captures every dMMR/MSI-H pathology result and shepherds it through genetic counseling referral, germline testing, and family cascade outreach — a chain with multiple potential failure points. Adjuvant nivolumab in the post-RNU setting introduces the same irAE surveillance burden as metastatic immunotherapy, requiring PRO collection, toxicity alert, and cycle scheduling integration. FGFR3 molecular profiling links genomic results to targeted therapy eligibility flags and ophthalmology referral automation.

Monitoring teams should prioritize canary transactions for the Lynch syndrome routing pathway and the FGFR3 result delivery pipeline, as delays in either directly affect eligibility for evidence-based interventions. Combined with robust surveillance scheduling validators and adjuvant nivolumab cycle adherence tracking, a well-instrumented UTUC informatics platform ensures that patients receive the right care — from germline counseling to targeted therapy — without critical workflows falling through the cracks.

Monitor your app with Vigilmon

Free plan — 5 monitors, no credit card required. Up and running in 60 seconds.

Start free →
← Back to all articles